NDAQ:MRNA - Post Discussion
Post by
Youhillman on Jan 28, 2021 4:16pm
Motley Fool buy recommendation...
I'm part of their 'Rule Breakers' newsletter service, their track record has been outstanding in the past year or so.
They came out with this recommendation today, so I bought in at $162. I'm obviously betting they are right!
The Foolish Bottom Line Moderna is a true Rule Breaker — a company that deliberately stayed in stealth mode for as long as possible, then raised an amazing $2.7 billion in venture capital on the strength of what was, at the time, a largely unproven concept. The past year has put the company in a position it would have otherwise taken years to reach. The stock is more expensive, yes, but the company has cash, cache, and a large pipeline it can move forward aggressively. If mRNA continues to live up to its promise, Moderna will be able to address disease in an entirely new way, making today's valuation look like a bargain.
Be the first to comment on this post